Stada Delays IPO Plans Amid Market Volatility

German pharmaceutical company Stada is evaluating its ownership options, including a potential initial public offering (IPO), after reports emerged that its planned listing has been postponed to September due to market volatility. The company, which is majority-owned by private equity firms Bain Capital and Cinven, had initially aimed to launch the share sale this week. If the IPO proceeds as expected, it could generate around 1.5 billion euros and position Stada among the largest IPOs in Europe this year. Stada is known for products such as Grippostad and Ladival, and its valuation could reach 10 to 12 billion euros. The exact timing of the IPO remains uncertain, with market conditions potentially influencing the launch date, which could be as soon as April 11. Stada has recently appointed Andreas Fibig as its new chairman, marking a significant step towards the anticipated listing.